In “≥ 2nd line” (RR 1.20, 95% CI 0.97-1.50, p = 0.10, Fig. 5b), anti-PD-L1 (control group) (RR 1.23, 95% CI 0.52-2.91, p = 0.64, Fig. 5d), gastric or esophagogastric cancer (RR 1.16, 95% CI 0.80-1.69, p = 0.43, Fig. 4g) and head and neck squamous cell carcinoma (RR 2.20, 95% CI 0.25-19.53, p = 0.48, Fig. 5h), there was no significant change in DCR of ICI combination therapy and ICI monotherapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.